News | Athena Pharmaceutiques

News

Recent News

May, 2026

Athena Drug Delivery Solutions (Athena), a global leader in advanced drug delivery technologies, is pleased to announce the successful completion of the dossier for its Nefopam Hydrochloride Orally Disintegrating Tablets (ODT) 30 mg. This milestone paves the way for an imminent regulatory submission in the European market on behalf of its client, GEMAPHARMA.

Learn more

April 16th, 2026

Athena marks a new milestone in its development in France with the commercialization of SECNOL® (secnidazole), led by its subsidiary MEDIPHA Santé. This initiative reflects the Group’s ambition to bring targeted therapeutic solutions to the French market, supported by its integrated industrial and pharmaceutical expertise.

Learn more

April 8th, 2026

Athena Pharmaceutiques Celebrates 15 Years of Innovation and Global Growth in Mumbai The milestone anniversary highlights the company’s evolution from an ambitious foundational venture to an international pharmaceutical powerhouse with over 500 employees.

Athena Pharmaceutiques officially marked its 15th anniversary this week, hosting a celebration at its headquarters in Mumbai. The event honored the decade-and-a-half journey of the organization, reflecting on its growth from a nascent Mumbai-based firm to a globally recognized name in the pharmaceutical industry.

Learn more

February 20th, 2026

Athena Pharmaceutiques, a leading global player in value-added drug delivery and specialty generics, is proud to announce the successful registration and upcoming market entry of Trazodone PR Tablet in Brazil. This milestone follows the company’s formal incorporation in the territory on February 20, 2026, marking a significant expansion of its neuropsychiatry portfolio in Latin America.

Learn more

July 2nd, 2025

Substipharm SAS and Athena Pharmaceutiques, are proud to announce the acquisition of a majority stake in Vectans Pharma SAS, a pharmaceutical company recognized for its proprietary Lauriad® muco-adhesive drug delivery technology.

This alliance leverages the strengths of Substipharm and Athena to fast-track Vectans Pharma’s innovation pipeline and broaden its global footprint. It creates a robust platform to grow the Lauriad® franchise, enter new markets, and enhance value through streamlined operations.

Learn more

June 3rd, 2024

Athena Pharmaceutiques is thrilled to announce the acquisition of Medipha Santé, expert in pharmaceutical commercialization, regulatory affairs and pharmacovigilance.

This operation is part of Athena Pharmaceutiques' plan to strengthen its expertise and presence on the drug delivery market, and broaden its service offering in regulatory management, becoming a full service platform capable of developing, producing and marketing around the world.

Learn more